Compare · DVA vs LSTA
DVA vs LSTA
Side-by-side comparison of DaVita Inc. (DVA) and Lisata Therapeutics Inc. (LSTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DVA and LSTA operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- DVA is the larger of the two at $10.01B, about 346.5x LSTA ($28.9M).
- Over the past year, DVA is up 8.0% and LSTA is up 31.6% - LSTA leads by 23.5 points.
- DVA has been more active in the news (3 items in the past 4 weeks vs 2 for LSTA).
- DVA has more recent analyst coverage (12 ratings vs 0 for LSTA).
- Company
- DaVita Inc.
- Lisata Therapeutics Inc.
- Price
- $151.81-2.06%
- $3.21-3.89%
- Market cap
- $10.01B
- $28.9M
- 1M return
- -2.17%
- -36.12%
- 1Y return
- +8.05%
- +31.56%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 3
- 2
- Recent ratings
- 12
- 0
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Latest DVA
- SEC Form DEFA14A filed by DaVita Inc.
- SEC Form DEF 14A filed by DaVita Inc.
- DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call
- Amendment: SEC Form SCHEDULE 13G/A filed by DaVita Inc.
- DaVita Highlights Continued Progress in Value-Based Kidney Care as CKCC Results Show Year-Over-Year Improvement
- Director Arway Pamela M was granted 332 shares, increasing direct ownership by 1% to 26,695 units (SEC Form 4)
- Director Desoer Barbara J was granted 332 shares (SEC Form 4)
- Chief Operating Officer, DKC Maughan David Paul was granted 5,308 shares and covered exercise/tax liability with 13,107 shares, decreasing direct ownership by 6% to 114,467 units (SEC Form 4)
- Director Yale Phyllis R was granted 332 shares, increasing direct ownership by 2% to 14,313 units (SEC Form 4)
- Chief Executive Officer Rodriguez Javier was granted 20,900 shares, increasing direct ownership by 2% to 909,815 units (SEC Form 4)
Latest LSTA
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- SEC Form 8-K filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- SEC Form 10-K filed by Lisata Therapeutics Inc.
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure
- Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
- SEC Form SC14D9C filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement